Sarepta Shares Plummet 10% Amid New Adverse Event Report

Sarepta Therapeutics' shares fell 10% due to a new adverse event report of a patient experiencing drug-induced liver injury and increased liver enzyme levels. However, the company stated that the patient was already disclosed in previous safety updates and the case was classified as serious due to hospitalization. Deutsche Bank maintains a Sell rating and a $12 price target.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) faced a significant setback as its shares fell by 10% following a new adverse event report. The report revealed a patient experiencing drug-induced liver injury and increased liver enzyme levels. The company stated that the patient had been previously disclosed in earlier safety updates and that the case was classified as serious due to hospitalization.

The adverse event report comes at a critical juncture for Sarepta, which has been under scrutiny for its gene therapy ELEVIDYS. In March 2025, Sarepta announced that a patient had died following treatment with ELEVIDYS, leading to a substantial drop in the stock price. Subsequent disclosures, including halts in recruitment and dosing in clinical studies, have continued to impact the company's stock performance.

Deutsche Bank maintains a Sell rating on Sarepta, with a $12 price target, reflecting the ongoing concerns over the safety and regulatory risks associated with ELEVIDYS. The latest adverse event report has added to these concerns, potentially impacting investor confidence and the company's future prospects.

Investors who purchased or acquired Sarepta securities between June 22, 2023, and June 24, 2025, are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights. The law firm has filed a class action lawsuit against Sarepta, alleging materially false and misleading statements regarding ELEVIDYS and its revenue outlook [1].

References:
[1] https://www.morningstar.com/news/globe-newswire/9517642/sarepta-final-deadline-alert-bragar-eagel-squire-pc-reminds-investors-that-a-class-action-lawsuit-has-been-filed-against-sarepta-therapeutics-inc-and-encourages-investors-to-contact-the-firm-before-the-august-25th-deadline